Media coverage about VIVUS (NASDAQ:VVUS) has trended somewhat positive on Tuesday, Accern Sentiment reports. The research firm identifies positive and negative news coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. VIVUS earned a daily sentiment score of 0.20 on Accern’s scale. Accern also assigned media coverage about the biopharmaceutical company an impact score of 46.1168635440846 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
These are some of the news headlines that may have effected Accern’s scoring:
- VIVUS (VVUS) Rating Lowered to Hold at Zacks Investment Research (americanbankingnews.com)
- -$0.13 EPS Expected for VIVUS, Inc. (VVUS) This Quarter (americanbankingnews.com)
- Shooting From The Hip: Quant Update on VIVUS, Inc. (NasdaqGS:VVUS) as Price Index Touches 0.42870 – Clawson News (clawsonnews.com)
- Chief Medical Officer of Vivus Inc (NASDAQ:VVUS), Varghese Santosh T, sells 444 shares worth $226 (empowerednews.net)
VVUS has been the subject of a number of research reports. ValuEngine cut shares of VIVUS from a “sell” rating to a “strong sell” rating in a research note on Friday, December 1st. Zacks Investment Research cut shares of VIVUS from a “buy” rating to a “hold” rating in a research note on Saturday.
VIVUS (NASDAQ:VVUS) last released its quarterly earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($0.06) EPS for the quarter, topping analysts’ consensus estimates of ($0.13) by $0.07. VIVUS had a net margin of 26.71% and a return on equity of 344.23%. The business had revenue of $15.19 million for the quarter, compared to analyst estimates of $16.00 million. During the same period last year, the firm earned ($0.09) earnings per share. VIVUS’s revenue for the quarter was up 13.8% compared to the same quarter last year. equities analysts anticipate that VIVUS will post -0.32 EPS for the current fiscal year.
VIVUS Company Profile
VIVUS, Inc is a biopharmaceutical company. The Company operates in the development and commercialization of therapeutic products segment. It provides over two therapies approved by the Food and Drug Association (FDA), which include Qsymia (phentermine and topiramate extended-release) for chronic weight management and STENDRA (avanafil) for erectile dysfunction (ED).
Receive News & Ratings for VIVUS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for VIVUS and related companies with MarketBeat.com's FREE daily email newsletter.